leadf
logo-loader
viewOncoSil Medical Ltd

OncoSil Medical with Proactive at ASX Small and Mid-Cap Conference

OncoSil Medical Ltd (ASX:OSL) chief executive officer Daniel Kenny speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020. 

The medical device company is seeking to advance radiation for cancer patients. OncoSil Medical’s lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound.

Quick facts: OncoSil Medical Ltd

Price: 0.13 AUD

ASX:OSL
Market: ASX
Market Cap: $107.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Davide Bosio previews hotly anticipated IPOs for Miramar Resources and Zebit

Davide Bosio from Shaw and Partners says it's been a terrific start to the listing process for Miramar Resources, a junior West Australia exploration company. ''We opened up the offer and closed literally on the same day raising $8mln''. Bosio adds that Zebit is still on track to list on the ASX...

1 day, 14 hours ago

2 min read